These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

674 related items for PubMed ID: 18030008

  • 1. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
    Miyanaga N, Akaza H.
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
    [Abstract] [Full Text] [Related]

  • 2. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N.
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [Abstract] [Full Text] [Related]

  • 3. [Neoadjuvant chemotherapy for invasive bladder cancer].
    Kageyama Y, Kihara K.
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1838-44. PubMed ID: 11729476
    [Abstract] [Full Text] [Related]

  • 4. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M, Kotake T.
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.
    Sternberg CN, Parmar MK.
    J Clin Oncol; 2001 Sep 15; 19(18 Suppl):21S-26S. PubMed ID: 11560967
    [No Abstract] [Full Text] [Related]

  • 6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 15; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 7. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M.
    Cancer; 2003 Apr 01; 97(7):1644-52. PubMed ID: 12655521
    [Abstract] [Full Text] [Related]

  • 8. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer.
    Takata R, Obara W, Fujioka T.
    Aktuelle Urol; 2010 Jan 01; 41 Suppl 1():S41-5. PubMed ID: 20094952
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR, Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.
    Can J Urol; 2002 Oct 01; 9(5):1625-33. PubMed ID: 12431323
    [Abstract] [Full Text] [Related]

  • 10. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ-preserving therapy in carefully selected patients.
    Heidenreich A.
    Eur Urol; 2008 Jul 01; 54(1):21-3. PubMed ID: 18262722
    [No Abstract] [Full Text] [Related]

  • 11. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y, Nishiyama H, Watanabe J, Teramukai S, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, Ogawa O.
    Int J Clin Oncol; 2005 Apr 01; 10(2):133-8. PubMed ID: 15864700
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer.
    Bajorin DF.
    J Clin Oncol; 2001 Sep 15; 19(18 Suppl):17S-20S. PubMed ID: 11560966
    [No Abstract] [Full Text] [Related]

  • 14. Neoadjuvant treatment for invasive bladder cancer: is it worthwhile?
    Hall RR.
    Acta Urol Belg; 1996 May 15; 64(2):39-42. PubMed ID: 8701809
    [No Abstract] [Full Text] [Related]

  • 15. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation.
    Sternberg CN.
    Semin Oncol; 2007 Apr 15; 34(2):122-8. PubMed ID: 17382795
    [Abstract] [Full Text] [Related]

  • 16. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
    Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP.
    Clin Cancer Res; 2000 Dec 15; 6(12):4866-73. PubMed ID: 11156246
    [Abstract] [Full Text] [Related]

  • 17. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M, Miyanaga N, Tokuuye K, Saida Y, Ohara K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Hattori K, Shimazui T, Akaza H, Akine Y.
    Int J Radiat Oncol Biol Phys; 2006 Apr 01; 64(5):1371-9. PubMed ID: 16580495
    [Abstract] [Full Text] [Related]

  • 18. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Herr HW.
    Eur Urol; 2008 Jul 01; 54(1):126-32. PubMed ID: 18248875
    [Abstract] [Full Text] [Related]

  • 19. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y, Izumi K, Miwa S, Kadono Y, Konaka H, Mizokami A, Namiki M.
    Anticancer Res; 2013 Oct 01; 33(10):4497-503. PubMed ID: 24123021
    [Abstract] [Full Text] [Related]

  • 20. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
    Milowsky MI, Stadler WM, Bajorin DF.
    BJU Int; 2008 Nov 01; 102(9 Pt B):1339-44. PubMed ID: 19035902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.